Agentix (AGTX) 10-Q 14 Feb 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2023	Feb. 07, 2024
Cover [Abstract]
Entity Registrant Name	AGENTIX CORP.
Entity Central Index Key	0001603345
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		40,066,931
Entity File Number	000-55383
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-2876282
Entity Address Address Line 1	32932 Pacific Coast Highway
Entity Address Address Line 2	14-254
Entity Address City Or Town	Dana Point
Entity Address State Or Province	CA
Entity Address Postal Zip Code	92629
City Area Code	321
Local Phone Number	299-2041
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current Assets
Cash	$ 3,480	$ 12,369
Prepaid expense and other current assets	108,471	249,023
Total current assets	111,951	261,392
Total assets	111,951	261,392
Current Liabilities
Accounts payable	1,106,383	1,057,215
Accounts payable - related parties	1,729,323	1,394,230
Note payable - related party	100,000	50,000
Accrued expenses	22,221	9,110
Total current liabilities	2,957,927	2,510,555
Long Term Liabilities	0	0
Total liabilities	2,957,927	2,510,555
Commitments and Contingencies	0	0
Stockholders' Deficit
Common stock par value $0.001: 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively	40,067	40,067
Common stock to be issued (357,102 at December 31, 2023 and March 31, 2023, respectively)	53,535	53,535
Additional paid-in capital	3,025,796	3,025,796
Accumulated other comprehensive income	(13,892)	765
Accumulated deficit	(5,951,482)	(5,369,326)
Total stockholders' deficit	(2,845,976)	(2,249,163)
Total liabilities and stockholders' deficit	$ 111,951	$ 261,392

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Mar. 31, 2023
Consolidated Balance Sheets
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	40,066,951	40,066,951
Common stock, shares outstanding	40,066,951	40,066,951
Common stock to be issued	357,102	357,102

Unaudited Consolidated Statemen

Unaudited Consolidated Statement of Operations - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating Expenses
Professional fees	$ 78,040	$ 139,821	$ 315,347	$ 296,673
Research and development	(87,304)	192,032	129,244	527,676
General and administrative expenses	25,110	21,785	325,545	118,273
Total operating expenses	15,846	353,638	770,136	942,622
Loss from operations	(15,846)	(353,638)	(770,136)	(942,622)
Other (income) expense
Foreign exchange loss (gain)	(25,434)	0	(3,212)	0
Interest expense	3,214	0	13,851	0
Interest income	0	0	(248)	0
Other income	0	0	(198,371)	0
Other income, net	(22,220)	0	(187,980)	0
Income (loss) before Income tax provision	6,374	(353,638)	(582,156)	(942,622)
Income tax provision	0	0	0	0
Net income (loss)	6,374	(353,638)	(582,156)	(942,622)
Other comprehensive income
Change in foreign currency translation, net of tax	(36,889)	(2,225)	(14,657)	(2,225)
Total other comprehensive loss	$ (30,515)	$ (355,863)	$ (596,813)	$ (944,847)
Income (loss) per share- Basic and diluted	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average common shares outstanding- Basic and diluted	40,066,951	39,116,951	40,066,951	38,995,307

Unaudited Consolidated Statem_2

Unaudited Consolidated Statement of Changes in Stockholders (Deficit) Equity - USD ($)	Total	Common Stock [Member]	Common Stock to be Issued	Additional Paid-in Capital	Other Comprehensive loss	Accumulated Deficit
Balance, shares at Mar. 31, 2022		38,916,951
Balance, amount at Mar. 31, 2022	$ (1,076,998)	$ 38,917	$ 0	$ 2,879,606	$ 0	$ (3,995,521)
Net Loss	(164,654)				0	(164,654)
Balance, shares at Jun. 30, 2022		38,916,951
Balance, amount at Jun. 30, 2022	(1,241,652)	$ 38,917	0	2,879,606	0	(4,160,175)
Balance, shares at Mar. 31, 2022		38,916,951
Balance, amount at Mar. 31, 2022	(1,076,998)	$ 38,917	0	2,879,606	0	(3,995,521)
Net Loss	(942,622)
Balance, shares at Dec. 31, 2022		39,116,951
Balance, amount at Dec. 31, 2022	(1,863,170)	$ 39,117	108,675	2,929,406	(2,225)	(4,938,143)
Balance, shares at Jun. 30, 2022		38,916,951
Balance, amount at Jun. 30, 2022	(1,241,652)	$ 38,917	0	2,879,606	0	(4,160,175)
Net Loss	(424,330)				0	(424,330)
Shares issued for cash, shares		200,000
Shares issued for cash, amount	50,000	$ 200		49,800
Balance, shares at Sep. 30, 2022		39,116,951
Balance, amount at Sep. 30, 2022	(1,615,982)	$ 39,117	0	2,929,406	0	(4,584,505)
Net Loss	(353,638)				0	(353,638)
Shares issued to board member for services	30,600		30,600
Shares issued to consultants for services	78,075		78,075
Foreign exchange translation loss	(2,225)				(2,225)
Balance, shares at Dec. 31, 2022		39,116,951
Balance, amount at Dec. 31, 2022	(1,863,170)	$ 39,117	108,675	2,929,406	(2,225)	(4,938,143)
Balance, shares at Mar. 31, 2023		40,066,951
Balance, amount at Mar. 31, 2023	(2,249,163)	$ 40,067	53,535	3,025,796	765	(5,369,326)
Net Loss	(409,558)					(409,558)
Foreign exchange translation loss	6,248				6,248
Balance, shares at Jun. 30, 2023		40,066,951
Balance, amount at Jun. 30, 2023	(2,652,473)	$ 40,067	53,535	3,025,796	7,013	(5,778,884)
Balance, shares at Mar. 31, 2023		40,066,951
Balance, amount at Mar. 31, 2023	(2,249,163)	$ 40,067	53,535	3,025,796	765	(5,369,326)
Net Loss	(582,156)
Balance, shares at Dec. 31, 2023		40,066,951
Balance, amount at Dec. 31, 2023	(2,845,976)	$ 40,067	53,535	3,025,796	(13,892)	(5,951,482)
Balance, shares at Jun. 30, 2023		40,066,951
Balance, amount at Jun. 30, 2023	(2,652,473)	$ 40,067	53,535	3,025,796	7,013	(5,778,884)
Net Loss	(178,972)					(178,972)
Foreign exchange translation loss	15,984				15,984
Balance, shares at Sep. 30, 2023		40,066,951
Balance, amount at Sep. 30, 2023	(2,815,461)	$ 40,067	53,535	3,025,796	22,997	(5,957,856)
Net Loss	6,374					6,374
Foreign exchange translation loss	(36,889)				(36,889)
Balance, shares at Dec. 31, 2023		40,066,951
Balance, amount at Dec. 31, 2023	$ (2,845,976)	$ 40,067	$ 53,535	$ 3,025,796	$ (13,892)	$ (5,951,482)

Unaudited Consolidated Statem_3

Unaudited Consolidated Statement of Cash Flows - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net loss	$ (582,156)	$ (942,622)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of stock issued for software	23,682	15,000
Stock issued for services	0	108,675
Changes in operating assets and liabilities:
Prepayments and other current assets	116,869	(109,963)
Accrued expenses, accounts payable and accounts payable-related party	397,373	881,669
Net Cash Provided by (Used in) Operating Activities	(44,232)	(47,241)
Cash Flows from Investing Activities	0	0
Cash Flows from Financing Activities
Proceeds from issuance of debt	120,000	0
Principal payments of debt	(70,000)	0
Proceeds from issuance of common stock	0	50,000
Net Cash Provided by Financing Activities	50,000	50,000
Effects of Foreign Exchange Rate Changes on Cash	(14,657)	(2,225)
Net Change in Cash	(8,889)	534
Cash - beginning of reporting period	12,369	145
Cash - end of reporting period	$ 3,480	$ 679

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Dec. 31, 2023
Organization and Basis of Presentation
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Description of the Company FairWind Energy, Inc. (the "Company") was incorporated on April 18, 2013 under the laws of the State of Nevada. Effective June 17, 2019, the Company changed its name to Agentix Corp. In March 2022, the Company changed its fiscal year end from August to March. The Company is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Going Concern The Company’s unaudited consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the unaudited consolidated financial statements, the Company had an accumulated deficit on December 31, 2023 and a net loss. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Cash on hand as of December 31, 2023 was $3,480. The Company is attempting to commence operations and generate sufficient revenue; however, the Company’s cash position is not sufficient to support its daily operations and it will need further funding. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds. The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, GSL Healthcare, Inc., AB Merger LLC, Agentix Australia Pty Ltd, and Applied Biopharma, all 100% owned entities. Intercompany transactions and balances have been eliminated in consolidation.

Significant and Critical Accoun

Significant and Critical Accounting Policies and Practices	9 Months Ended
	Dec. 31, 2023
Significant and Critical Accounting Policies and Practices
Significant and Critical Accounting Policies and Practices	Note 2 - Significant and Critical Accounting Policies and Practices Basis of Presentation The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and with the rules and regulations of the United States Securities and Exchange Commission ("SEC") to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the audited financial statements of the Company for the reporting period ended March 31, 2023 and notes thereto contained in the Company’s Annual Report on Form 10-K. Prepayment Prepayments consisted of the following: · $104,274 and $199,347 as of December 31, 2023 and March 31, 2023, respectively, related to obligations for clinical research for which the Company is obligated to pay, but hasn’t recorded the expense as the related services were not completed by the vendor as of March 31, 2023. There were no similar prepayments as of March 31, 2022. · $nil and $21,797 as of December 31, 2023 and March 31, 2023, respectively, related to Goods and Services Tax (GST). GST relates to expenses and assets from the Company’s Agentix Australian Pty Ltd entity that is recognized net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. · $4,197 and $27,879 as of December 31, 2023 and March 31, 2023, respectively, related to shares issued for prepaid software. Fair Value of Financial Instruments The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments. Research and Development The Company follows paragraph 730-10-25-1 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 2 “Accounting for Research and Development Costs” “Research and Development Arrangements” Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include a. affiliates (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act) of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Deferred Tax Assets and Income Tax Provision The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. Earnings per Share Earnings per share (“EPS”) are the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants. Pursuant to ASC Paragraphs 260-10-45-45-21 through 260-10-45-45-23 Diluted EPS shall be based on the most advantageous conversion rate or exercise price from the standpoint of the security holder. The dilutive effect of outstanding call options and warrants (and their equivalents) issued by the reporting entity shall be reflected in diluted EPS by application of the treasury stock method unless the provisions of paragraphs 260-10-45-35 through 45-36 and 260-10-55-8 through 55-11 require that another method be applied. Equivalents of options and warrants include non-vested stock granted to employees, stock purchase contracts, and partially paid stock subscriptions (see paragraph 260–10–55–23). Anti-dilutive contracts, such as purchased put options and purchased call options, shall be excluded from diluted EPS. Under the treasury stock method: a. Exercise of options and warrants shall be assumed at the beginning of the period (or at time of issuance, if later) and common shares shall be assumed to be issued. b. The proceeds from exercise shall be assumed to be used to purchase common stock at the average market price during the period. (See paragraphs 260-10-45-29 and 260-10-55-4 through 55-5.) c. The incremental shares (the difference between the number of shares assumed issued and the number of shares assumed purchased) shall be included in the denominator of the diluted EPS computation. There were no dilutive common shares for the nine months ended December 31, 2023. Stock-Based Payments Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For non-employees, the Company follows ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under the ASU No. 2017-07, most of the guidance on stock payments to nonemployees is aligned with the requirements for share-based payments granted to employees. As such, most of the guidance in ASC 718 associated with employee share-based payments, including most requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. No stock options or warrants were issued or outstanding as of December 31, 2023 and March 31, 2023. Recent Accounting Pronouncements There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December 31, 2023, as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, that are of significance or potential significance to the Company.

Related Parties

Related Parties	9 Months Ended
	Dec. 31, 2023
Related Parties
Related Parties	Note 3 – Related Parties SBS Management LLC During the nine months ended December 31, 2023, the Company incurred $117,000 of management and IT fees; $45,000 for reimbursement of rent; and $57,692 of advances to the Company to cover certain operating expenses and accounts payable from SBS Management LLC, a company controlled by Mr. Scott Stevens who is a shareholder of the Company. As of December 31, 2023 and March 31, 2023, $772,635 and $552,943, respectively, was included in Accounts payable – related party on the accompanying unaudited balance sheet. During the nine months ended December 31, 2022, the Company incurred $117,000 of management and IT fees; $45,000 for reimbursement of rent; and $33,703 of advances to the Company to cover certain operating expenses and accounts payable from SBS Management LLC. During the nine months ended December 31, 2022, the Company granted 250,000 shares of its common stock to SBS Management LLC in exchange for services previously provided. The shares were valued at a price of $0.17 per share or $42,375, which was the then fair market value as per the market closing price as of the date of the Company’s grant of these shares. Gray’s Peak Capital During the nine ended December 31, 2023 and 2022, Gray’s Peak Capital (“Gray’s Peak”), a company founded by a shareholder of the Company, made advances to the Company to cover certain operating expenses. These advances are unsecured, non-interest bearing, with no formal terms of repayment. As of December 31, 2023 and March 31, 2023, the amounts due Gray’s Peak for these advances were $260,688 and $248,187, respectively, and was included in accounts payable – related parties on the accompanying balance sheet. Gray’s Peak Capital – Notes Payable On January 15, 2023 and June 15, 2023, the Company entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC. For 30 days after the date of the Note, the Note bears interest at 7.5%. After the 30th day, the Note bears interest at 2% per month until paid in full. The Note matures and becomes due and payable in full on the 4 th th The Notes are secured by a pledge by the Company of favor of Gray’s Peak of all of the assets and property of the Company, including without limitation all R&D tax credits, goods, tangible property, machinery, owned equipment, furniture, fixtures, vehicles, parts, accounts, deposit accounts, letter-of-credit rights, chattel paper, contract rights, documents, instruments, investment property, choses in action, general intangibles, goodwill and intellectual property, of any kind or nature, wherever located, in which Company has an interest now or in the future, and which are now existing or hereafter created or acquired, together with any and all additions, replacements, accessions and substitutions thereto or therefore, and any proceeds thereof excluding equipment leased by the Company (collectively called the “Collateral”). Gray’s Peak interest is senior to the unsecured debt or lenders of the Company and the Company’s equity holders. Upon the occurrence of any Event of Default, as defined in the agreement, the principal sum, all accrued and unpaid interest owing thereon and all costs and expenses payable pursuant to this Note, shall, at the sole option of Gray’s Peak and with submission of written notice, become immediately due and payable. As of December 31, 2023 and March 31, 2023, the principal balance outstanding was $100,000 and $50,000, respectively, of which the $50,000 outstanding balance as of March 31, 2023 was repaid in September 2023. The notes were included in notes payable – related party on the accompanying condensed balance sheet of which $12,271 and $1,643 of interest was accrued and included in accrued expenses as of December 31, 2023 and March 31, 2023, respectively. Management During the nine months ended December 31, 2023 and December 31, 2022, the Company incurred $103,350 and $93,000, respectively, of consulting fees from a consulting agreement with the Company’s President and Board member. As of December 31, 2023 and March, 31 2023, $471,850 and $368,500, respectively, was included in accounts payable – related party on the accompanying balance sheet. During the nine months ended December 31, 2022, the Company incurred $30,000 of consulting fees from a consulting and employment agreement with the Company’s then CEO. As of December 31, 2023 and March 31, 2023, $262,500 was included in accounts payable – related party on the accompanying balance sheet.

Equity

Equity	9 Months Ended
	Dec. 31, 2023
Equity
Equity	Note 4 – Equity As of December 31, 2023 and March 31, 2023, the Company has authorized 50,000,000 shares of common stock at a par value of $0.001 per share and had issued and outstanding shares of common stock of 40,066,951. Shares to be Issued The Company had previously granted 250,000 shares of its common stock for services previously provided. As of December 31, 2023 and March 31, 2023, these shares had not been issued and were included in common stock to be issued in the consolidated balance sheet. The Company had previously issued shares of its common stock in exchange for a one-year software subscription. As of December 31, 2023 and March 31, 2023, 107,102 shares granted had not been issued and were included in common stock to be issued in the consolidated balance sheet. Shares Issued for Cash During the nine months ended December 31, 2022, the Company sold 200,000 shares of its common stock to an accredited investor for $0.25 per share for total proceeds of $50,000. Shares Issued for Services During the nine months ended December 31, 2022, the Company granted 300,000 and 200,000 shares of its common stock to a board member and certain consultants, respectively, in exchange for services previously provided. The shares were valued at a price of $0.10 per share or $66,300, which was the then fair market value as per the market closing price as of the date of the Company’s grant of these shares.

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2023
Subsequent Events
Subsequent Events	Note 5 – Subsequent Events In January 2024, Gray’s Peak Private Credit LLC advanced $8,000 to the Company under the June 15, 2023 Note (see Note 3). In accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2023 through the date these financial statements were issued and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Significant and Critical Acco_2

Significant and Critical Accounting Policies and Practices (Policies)	9 Months Ended
	Dec. 31, 2023
Significant and Critical Accounting Policies and Practices
Basis of Presentation	The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and with the rules and regulations of the United States Securities and Exchange Commission ("SEC") to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the audited financial statements of the Company for the reporting period ended March 31, 2023 and notes thereto contained in the Company’s Annual Report on Form 10-K.
Prepayment	Prepayments consisted of the following: · $104,274 and $199,347 as of December 31, 2023 and March 31, 2023, respectively, related to obligations for clinical research for which the Company is obligated to pay, but hasn’t recorded the expense as the related services were not completed by the vendor as of March 31, 2023. There were no similar prepayments as of March 31, 2022. · $nil and $21,797 as of December 31, 2023 and March 31, 2023, respectively, related to Goods and Services Tax (GST). GST relates to expenses and assets from the Company’s Agentix Australian Pty Ltd entity that is recognized net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. · $4,197 and $27,879 as of December 31, 2023 and March 31, 2023, respectively, related to shares issued for prepaid software.
Fair Value of Financial Instruments	The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.
Research and Development	The Company follows paragraph 730-10-25-1 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 2 “Accounting for Research and Development Costs” “Research and Development Arrangements”
Related Parties	The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include a. affiliates (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act) of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Deferred Tax Assets and Income Tax Provision	The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.
Earnings per Share	Earnings per share (“EPS”) are the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants. Pursuant to ASC Paragraphs 260-10-45-45-21 through 260-10-45-45-23 Diluted EPS shall be based on the most advantageous conversion rate or exercise price from the standpoint of the security holder. The dilutive effect of outstanding call options and warrants (and their equivalents) issued by the reporting entity shall be reflected in diluted EPS by application of the treasury stock method unless the provisions of paragraphs 260-10-45-35 through 45-36 and 260-10-55-8 through 55-11 require that another method be applied. Equivalents of options and warrants include non-vested stock granted to employees, stock purchase contracts, and partially paid stock subscriptions (see paragraph 260–10–55–23). Anti-dilutive contracts, such as purchased put options and purchased call options, shall be excluded from diluted EPS. Under the treasury stock method: a. Exercise of options and warrants shall be assumed at the beginning of the period (or at time of issuance, if later) and common shares shall be assumed to be issued. b. The proceeds from exercise shall be assumed to be used to purchase common stock at the average market price during the period. (See paragraphs 260-10-45-29 and 260-10-55-4 through 55-5.) c. The incremental shares (the difference between the number of shares assumed issued and the number of shares assumed purchased) shall be included in the denominator of the diluted EPS computation. There were no dilutive common shares for the nine months ended December 31, 2023.
Stock-Based Payments	Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. For non-employees, the Company follows ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under the ASU No. 2017-07, most of the guidance on stock payments to nonemployees is aligned with the requirements for share-based payments granted to employees. As such, most of the guidance in ASC 718 associated with employee share-based payments, including most requirements related to classification and measurement, applies to nonemployee share-based payment arrangements. No stock options or warrants were issued or outstanding as of December 31, 2023 and March 31, 2023.
Recent Accounting Pronouncements	There have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December 31, 2023, as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, that are of significance or potential significance to the Company.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details Narrative) - USD ($)	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Cash	$ 3,480	$ 12,369	$ 679	$ 145
GSL Healthcare [Member]
Owned entity percentage	100%

Significant and Critical Acco_3

Significant and Critical Accounting Policies and Practices (Details Narrative) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Significant and Critical Accounting Policies and Practices
Prepayments	$ 104,274	$ 199,347
Goods And Services Tax	0	21,797
Shares issued for prepaid software, value	$ 4,197	$ 27,879

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Jan. 15, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Accounts payable - related party		$ 1,729,323		$ 1,729,323		$ 1,394,230
Note payable - related party						50,000
Accrued expenses		22,221		22,221		9,110
Consulting fees		78,040	$ 139,821	315,347	$ 296,673
CEO [Member]
Accounts payable - related party		262,500		262,500		262,500
Consulting fees					$ 30,000
SBS Management [Member]
Accounts payable - related party		772,635		772,635		552,943
Common stock shares issued					250,000
Price per share			$ 0.17		$ 0.17
Common stock shares value					$ 42,375
Management fees				117,000	117,000
Reimbursement of rent				45,000	45,000
Advances				57,692	33,703
Grays Peak [Member]
Accounts payable - related party		260,688		260,688		248,187
Note payable - related party		100,000		100,000		50,000
Accrued expenses		12,271		12,271		1,643
Secured Note	the Company entered into two separate Mezzanine Secured Note (“Notes”) in the principal amount up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC. For 30 days after the date of the Note, the Note bears interest at 7.5%. After the 30th day, the Note bears interest at 2% per month until paid in full
President and Board member [Member]
Accounts payable - related party		$ 471,850		471,850		$ 368,500
Consulting fees				$ 103,350	$ 93,000

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Common stock to be issued	357,102		357,102
Proceeds from sale of common stock	$ 0	$ 50,000
Sale of common stock shares		200,000
Price per share		$ 0.25
Common stock, shares par value	$ 0.001		$ 0.001
Common stock, shares authorized	50,000,000		50,000,000
Common stock, shares issued	40,066,951		40,066,951
Common stock, shares outstanding	40,066,951		40,066,951
Board members [Member]
Common stock grnated in exchange for services		300,000
Price per share		$ 0.10
Common stock shares value		$ 66,300
Consultants [Member]
Common stock grnated in exchange for services		200,000
Price per share		$ 0.10
Services [Member]
Common stock to be issued	250,000		250,000
Software Subscription [Member]
Common stock to be issued	107,102		107,102

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Jan. 31, 2024 USD ($)
Subsequent Event [Member] | Grays Peak [Member]
Advanced to company	$ 8,000